A ‘Speckulative’ Screen: High-Content MTS Against NLRP1 Mediated Inflammasome Formation
Sygnature Discovery presents a poster exploring the development of a robust high-content screening platform to uncover small molecule modulators of NLRP1-mediated inflammasome formation. This fixed-endpoint, image-based assay uses ASC::GFP-labelled cells to visualise inflammasome speck formation and assess the impact of 5,120 diverse compounds from Sygnature’s LeadFinder library to identify potential modulators of NLRP1 mediated inflammasome formation as a key pattern recognition receptor.
Our NLRP1 Inflammasome Screening Highlights
A fixed-endpoint assay was established to identify potential modulators of inflammasome formation.
- High-content imaging to track speck formation as a readout of inflammasome activation
- 5120-compound primary screen yielding 70+ modulating hits
- Potency profiling revealed multiple novel activators and inhibitors
Advancing Innate Immunity Research Through HTS Innovation
This study demonstrates how NLRP1 inflammasome screening, more specifically how automated high-content imaging and Sygnature’s integrated screening workflow can be effectively applied to innate immunity targets, enabling early-stage identification and validation of promising NLRP1 pathway modulators in drug discovery.
Download the poster to explore how Sygnature Discovery’s high-throughput screening platform is used for NLRP1 inflammasome formation.
Sygnature Discovery supports complex cell-based screening with high-content imaging, assay development, compound profiling, and target validation to drive drug discovery forward with the best chance at a successful hit finding and validation stage.